JNC Pharmaceuticals launches its newest brand, Zeftrianav!
Ceftriaxone is a cephalosporin antibiotic used in the treatment of bacterial infections in various parts of the body. It comes in the form of Powder for Solution for Injection & Injections.
We aim to fill a gap as the use of Ceftriaxone as an antibiotic against pulmonary diseases becomes increasingly popular. The Global Ceftriaxone Sodium for Pulmonary Diseases Market Size is projected to grow from USD 627.64 Million to USD 767.71 Million by 2032. In fact, Pneumonia and Tracheitis are some of its most common applications, while current technological advancements and rising consumer acceptance set the market on a sustainable path. Asia-Pacific happens to rank third among regions driving this development.
Other applications for Ceftriaxone include:
– Treatment of Epiglottitis
– Treatment of Ophthalmia Neonatorum
– Treatment of Arthritis Gonococcal
– Prophylaxis of Conjunctivitis Gonococcal Neonatal
– Treatment of Brain Abscess
– Treatment of Chancroid
– Treatment of Community
– Acquired Pneumonia
– Treatment of Epididymitis
– Treatment of Syphilis
– Treatment of Typhoid Fever
– Treatment of Whipple Disease
– Treatment of Prosthetic Joint Infection
– Treatment & Prophylaxis of Bacterial Endocarditis
– And more!
Zeftrianav is JNC Pharmaceuticals’ house brand for Ceftriaxone. It comes in the form of Powder for Solution for Injection, and can be found in many of our partner hospitals in CALABARZON such as Calamba Doctors’ Hospital, Unihealth Southwoods, and more.
It is also open for regional sub-distributorship in the Philippines. For further details on sub-distributorship, contact jn_carlo_pharmaceutical@yahoo.com or 0917-188-1680.